Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Common Equity (2020 - 2025)

Bio Essence has reported Common Equity over the past 6 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly results put Common Equity at -$2.1 million for Q4 2025, up 30.18% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (up 30.18% YoY), and the annual figure for FY2025 was -$2.1 million, up 30.18%.
  • Common Equity for Q4 2025 was -$2.1 million at Bio Essence, up from -$3.1 million in the prior quarter.
  • Over the last five years, Common Equity for BIOE hit a ceiling of -$1.2 million in Q2 2023 and a floor of -$3.4 million in Q1 2023.
  • Median Common Equity over the past 5 years was -$2.5 million (2021), compared with a mean of -$2.5 million.
  • Biggest five-year swings in Common Equity: soared 59.24% in 2023 and later tumbled 108.0% in 2025.
  • Bio Essence's Common Equity stood at -$2.4 million in 2021, then plummeted by 33.34% to -$3.2 million in 2022, then skyrocketed by 48.73% to -$1.7 million in 2023, then plummeted by 78.83% to -$3.0 million in 2024, then soared by 30.18% to -$2.1 million in 2025.
  • The last three reported values for Common Equity were -$2.1 million (Q4 2025), -$3.1 million (Q3 2025), and -$3.1 million (Q2 2025) per Business Quant data.